Patent · US Active

Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor

US11390625B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignee

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CN

Inventors

Lingyun WU · Shanghai, CN
Xile LIU · Shanghai, CN
Charles Z. Ding · San Mateo, US
Shuhui CHEN · Shanghai, CN
Lihong Hu · Shanghai, CN
Lele ZHAO · Shanghai, CN
Wei-Jian Pan · Pullman, US
Guoping HU · Shanghai, CN
Jian Li · Shanghai, CN
Ning Zhao · Tangxia, CN
Jun Zhao · New York, US

Key dates

Filing date	Jul 19, 2018
Grant date	Jul 19, 2022
Priority date	—
Expiry date	Jul 28, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.